FDA Greenlights Generics for MICARDIS Blood Pressure Pills
Published Date: 5/7/2026
Notice
Summary
The FDA has decided that MICARDIS tablets (20 mg and 80 mg) were not taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved, helping patients access affordable options without delays. If you use or make these meds, no sudden changes or extra costs are coming your way anytime soon!
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
MICARDIS Generics Can Continue
The FDA determined on May 7, 2026 that MICARDIS (telmisartan) tablets, 20 mg and 80 mg, were not withdrawn from sale for reasons of safety or effectiveness. Because of this, FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these products and may continue approving new ANDAs that refer to these products so long as they meet legal and regulatory requirements. MICARDIS (NDA 020850, originally approved November 10, 1998) will remain listed in the Orange Book’s “Discontinued Drug Product List.”
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in